Cover Image

Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases

Neovascular age-related macular degeneration (AMD) is a progressive eye disease and is a leading cause of vision loss in the Western world. Vascular endothelial growth factor inhibitors have become a mainstay of treatment for this disease. Currently, treatment options include three originator biolog...

Full description

Saved in:
Bibliographic Details
Main Authors: Van de Wiele, Victor L. (Author) , Hammer, Maximilian (Author) , Parikh, Ravi (Author) , Feldman, William B (Author) , Sarpatwari, Ameet (Author) , Kesselheim, Aaron S (Author)
Format: Article (Journal)
Language:English
Published: 22 February 2022
In: Journal of law and the biosciences
Year: 2022, Volume: 9, Issue: 1, Pages: 1-18
ISSN:2053-9711
DOI:10.1093/jlb/lsac001
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/jlb/lsac001
Get full text
Author Notes:Victor L. Van de Wiele, Maximilian Hammer, Ravi Parikh, William B. Feldman, Ameet Sarpatwari and Aaron S. Kesselheim
Description
Summary:Neovascular age-related macular degeneration (AMD) is a progressive eye disease and is a leading cause of vision loss in the Western world. Vascular endothelial growth factor inhibitors have become a mainstay of treatment for this disease. Currently, treatment options include three originator biologics with approvals for neovascular AMD (aflibercept, ranibizumab, and brolucizumab-dbll) and one biologic that is commonly used off-label for the condition (bevacizumab). In the USA, Medicare spending on these drugs consistently surpassed
Item Description:Gesehen am 19.05.2022
Physical Description:Online Resource
ISSN:2053-9711
DOI:10.1093/jlb/lsac001

Similar Items